Benzinga | May 20, 2021 06:18AM EDT

Genetron Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management

Genetron Holdings Limited ((&ldquo, Genetron Health&rdquo, or the &ldquo, Company&rdquo, , NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with JD Health, a subsidiary of JD.com, Inc., and the largest online healthcare platform in China. The two companies aim to create innovative solutions for full-cycle cancer management.

The partnership encompasses both online and offline components, and focuses on six key areas: consumer healthcare, digitization of liver disease management, government medical associations, sharing of customer screening resources, industry and user education, and consolidation of oncology doctors and experts on a single platform. The first phase of the partnership will focus on liver and lung cancer.

The Company will cooperate with JD Health to cover early cancer screening, molecular profiling, therapy selection, and drug resistance monitoring, leveraging the Company's HCCscreen(tm) liquid biopsy product for hepatocellular carcinoma and its NMPA-approved 8-gene lung cancer detection kit.

This agreement marks Genetron Health's implementation of an online healthcare platform as the fourth commercialization channel for HCCscreen(tm), in addition to its three existing channels: medical examination centers, public health projects, and hospitals. The partnership also reflects JD Health's goal to help manage cancer across all stages for its customers.

In May and June, the Company and JD Health will launch a series of HCCscreen(tm) marketing and educational activities for people at high risk of developing liver cancer. Meanwhile, JD Health's online network of doctors and retail pharmacies will have an option to use Genetron Health's 8-gene lung cancer detection kit to help non-small cell lung cancer patients make their therapy selection decisions.